Cargando…
Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells
Roburic acid (ROB) is a naturally occurred tetracyclic triterpenoid, and the anticancer activity of this compound has not been reported. Docetaxel (DOC) is the first-line chemotherapeutic agent for advanced stage prostate cancer but toxic side effects and drug resistance limit its clinical success....
Autores principales: | Wang, Xiao, Xuetao, Xu, Wu, Mengshuo, Wu, Panpan, Sheng, Zhaojun, Liu, Wenfeng, Ma, Yan-Yan, Zhao, Den-Gao, Zhang, Kun, Li, Dongli, Zheng, Xi, Goodin, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741252/ https://www.ncbi.nlm.nih.gov/pubmed/34986722 http://dx.doi.org/10.1080/14756366.2021.2018684 |
Ejemplares similares
-
Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer
por: Jiang, Sen, et al.
Publicado: (2018) -
The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer
por: Yu, Lin, et al.
Publicado: (2017) -
Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cells via down regulation of NF-κB, STAT3, and ERK activation
por: Ma, Yuran, et al.
Publicado: (2020) -
Complanatuside alleviates inflammatory cell damage induced by pro-inflammatory cytokines in skin keratinocytes
por: Wang, Xiao, et al.
Publicado: (2022) -
Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures
por: Li, Dongli, et al.
Publicado: (2020)